Immunotherapies for Alzheimer’s disease
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Antibodies targeting amyloid-β aggregates slow decline in Alzheimer’s disease
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“All three have shown efficacy in clearing Aβ plaque and slowing cognitive decline, but the risks of amyloid-related imaging abnormalities (ARIA) and their treatment costs are noteworthy.422–424”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [422]
Citations
Cites
Lecanemab in early Alzheimer's disease
van Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M., Kanekiyo, M., Li, D., Reyderman, L., Cohen, S., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2212948 · Cited by 5,678
The neuropathological diagnosis of Alzheimer's disease
DeTure, M. A., & Dickson, D. W. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0333-5 · Cited by 3,329
Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial
Sims, J. R., Zimmer, J. A., Evans, C. D., Lu, M., Ardayfio, P., Sparks, J., Wessels, A. M., Shcherbinin, S., Wang, H., Monkul Nery, E. S., et al. (2023) · JAMA · doi:10.1001/jama.2023.13239 · Cited by 2,932
Donanemab in Early Alzheimer’s Disease
Mintun, M. A., Lo, A. C., Duggan Evans, C., Wessels, A. M., Ardayfio, P. A., Andersen, S. W., Shcherbinin, S., Sparks, J., Sims, J. R., Brys, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2100708 · Cited by 1,728
Johnson, E. C. B., Dammer, E. B., Duong, D. M., Ping, L., Zhou, M., Yin, L., Higginbotham, L. A., Guajardo, A., White, B., Troncoso, J. C., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0815-6 · Cited by 1,001
Self-citationSperling, R. A., Jack, C. R., Black, S. E., Frosch, M. P., Greenberg, S. M., Hyman, B. T., Scheltens, P., Carrillo, M. C., Thies, W., Bednar, M. M., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.05.2351 · Cited by 857
Söderberg, L., Johannesson, M., Nygren, P., Laudon, H., Eriksson, F., Osswald, G., Möller, C., & Lannfelt, L. (2023) · Neurotherapeutics · doi:10.1007/s13311-022-01308-6 · Cited by 427
Developing the ATX(N) classification for use across the Alzheimer disease continuum
Hampel, H., Cummings, J., Blennow, K., Gao, P., Jack, C. R., & Vergallo, A. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00520-w · Cited by 327
Multiple Cerebral Hemorrhages in a Patient Receiving Lecanemab and Treated with t-PA for Stroke
Reish, N. J., Jamshidi, P., Stamm, B., Flanagan, M. E., Sugg, E., Tang, M., Donohue, K. L., McCord, M., Krumpelman, C., Mesulam, M.-M., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmc2215148 · Cited by 232
Alzheimer's disease: The right drug, the right time
Golde, T. E., DeKosky, S. T., & Galasko, D. (2018) · Science · doi:10.1126/science.aau0437 · Cited by 147
Self-citation
Research works printed but not linked: 1
- S. Budd Haeberlein , J. Prev. Alzheimers Dis. 9, 197 (2022).
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
Cell-type-directed network-correcting combination therapy for Alzheimer’s disease
Li, Y., Serras, C. P., Blumenfeld, J. R., Xie, M., Hao, Y., Deng, E., Chun, Y. Y., Holtzman, J., An, A., Yoon, S. Y., et al. (2025) · Cell · doi:10.1016/j.cell.2025.06.035 · Cited by 74
Amyloid-β-targeting immunotherapies for Alzheimer's disease
Jin, Y., Du, Q., Song, M., Kang, R., Zhou, J., Zhang, H., & Ding, Y. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.09.012 · Cited by 65
Greenberg, S. M., & van Veluw, S. J. (2024) · Stroke · doi:10.1161/strokeaha.124.044293 · Cited by 32
Fang, S., Zhang, K., Liu, D., Yang, Y., Hu, X., Xie, W., Diao, K., Rao, Z., Wang, D., & Yang, W. (2024) · Frontiers in Nutrition · doi:10.3389/fnut.2024.1408620 · Cited by 29
“During the past two decades, the primary therapeutic approaches for AD have encompassed interventions targeting anti-neurotoxic β -amyloid (A β ) aggregates, anti-Tau, anti-neuroinflammatory, neuroprotective agents, and brain stimulation, among others (2–4).”
Background
Metadata
- Authors
- Golde, T. E., & Levey, A. I.
- Affiliations
- Emory University (US)
- Venue
- Science
- Published
- 2023-12-15
- Volume
- 382
- Issue
- 6676
- Pages
- 1242-1244
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W4389764088
- Cited by
- 66
- References
- 14
- Citations by year
- 2026: 13 · 2025: 22 · 2024: 31
- FWCI
- 11.73
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, immunotherapy, amyloid-beta, anti-amyloid antibodies, amyloid-beta aggregates, cognitive decline
- MeSH terms
- Alzheimer Disease, Antibodies, Clinical Trials as Topic, Humans, Immunotherapy, Amyloid beta-Peptides, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Immunotherapies for Alzheimer’s disease. https://app.cochat.ai/papers/10.1126/science.adj9255
- The paper
- Golde, T. E., & Levey, A. I. (2023). Immunotherapies for Alzheimer’s disease. Science. https://doi.org/10.1126/science.adj9255
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.